Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)

BACKGROUND: Reduction in cardiovascular death and hospitalization for heart failure (HHF) was recently reported with the sodium-glucose cotransporter-2 inhibitor (SGLT-2i) empagliflozin in patients with type 2 diabetes mellitus who have atherosclerotic cardiovascular disease. We compared HHF and dea...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Circulation
Main Authors: Kosiborod, Mikhail, Cavender, Matthew A., Fu, Alex Z., Wilding, John P., Khunti, Kamlesh, Holl, Reinhard W., Norhammar, Anna, Birkeland, Kåre I., Jørgensen, Marit Eika, Thuresson, Marcus, Arya, Niki, Bodegård, Johan, Hammar, Niklas, Fenici, Peter
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2017
Assuntos:
Original Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5515629/
https://ncbi.nlm.nih.gov/pubmed/28522450
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.117.029190
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados